Addressing the challenge of screening DNA-LNP formulations for targeting the brain_2

Developing hundreds of LNP formulations rapidly for in vitro screening is a significant challenge, particularly when considering multiplexing LNPs using barcoding strategies to increase throughput.
Furthermore, transitioning LNP production processes from screening to process development is often fraught with obstacles. Equipment changes result in resource wastage and demanding process re-validation, making the transition to the next stage a complex undertaking.
In this webinar, Razieh Karamzadeh will present data from experiments conducted at Karolinska Institute using Unchained Labs’ Sunscreen and Sunshine systems for production of DNA-LNPs for in vitro screening, then scaling-up selected LNPs for in vivo studies.
Razieh will demonstrate how she reproducibly created DNA-LNPs for in vitro 2D and 3D culture screening and in vivo testing. Combining formulation screening with 3D culture, this approach addressed some of the challenges of extra-hepatic delivery.
Razieh will also demonstrate how the use of both systems simplified the process of testing hundreds of formulations, followed by early scale-up for more comprehensive testing. This streamlined approach significantly accelerated the transition from large multiplexed LNP screens to process development of selected formulations, and can ultimately facilitate GMP production by maintaining consistent pumping and mixing technologies.